RxDoctor Payments DataLook up a doctor →

Tuan Vu, MD

Neurology · Tampa, FLNPI 1679503007

Payments from drug & device makers

$7,863,892in general payments, 2019–2025

Across 2,791 payments — averaging $2817.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$2.7M
  • AstraZeneca$1.5M
  • Argenx US, Inc.$1.3M
  • Regeneron$367K
  • Biogen$226K
  • Janssen Research & Development, LLC$225K
  • plus $1.5M from 39 others
$120,801in research payments, 2019–2025

Across 36 payments — averaging $3355.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$99K
  • UCB, Inc.$15K
  • Sanofi US Services Inc.$2K
  • Biogen$2K
  • Regeneron$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Behring499$2,730,959
AstraZeneca596$1,492,107
Argenx US, Inc.454$1,320,107
Regeneron515$367,463
Biogen14$226,429
Janssen Research & Development, LLC41$224,909
Ipsen Pharma SAS207$196,165
Orion Corporation41$189,208
UCB SA44$150,999
Amgen(2 entities)11$101,681
Harmony Biosciences LLC29$86,180
Mallinckrodt Enterprises LLC11$83,138
Sanofi12$81,323
Tanabe Pharma America, Inc.34$71,646
Mitsubishi Tanabe Pharma Development America, Inc.16$61,669
UCB Biosciences Inc.13$46,942
AbbVie(2 entities)88$46,357
Takeda Pharmaceuticals U.S.A., Inc.32$45,461
Octapharma USA, Inc.11$40,084
Amylyx Pharmaceuticals, Inc.15$39,212
Apellis Pharmaceuticals, Inc.9$37,910
Ares Trading SA7$24,545
F. Hoffmann-la Roche AG2$23,463
PTC Therapeutics, Inc.3$20,280
Bioverativ Therapeutics Inc.1$20,071
Johnson & Johnson16$18,284
Bio Products Laboratory USA, Inc.8$18,055
Mallinckrodt Hospital Products Inc.5$16,641
Shire North American Group Inc2$14,500
Grifols Therapeutics LLC4$12,631
Biohaven Pharmaceutical Holding Company Ltd.5$12,277
Janssen Global Services, LLC13$7,756
UCB, Inc.12$7,005
Ipsen Innovation1$6,825
UCB GmbH1$5,964
Sanofi US Services Inc.2$5,850
Catalyst Pharmaceuticals, Inc.8$4,407
Janssen Scientific Affairs, LLC1$2,250
Ipsen Biopharmaceuticals, Inc1$2,175
Biocryst Pharmaceuticals, Inc.1$580
Alnylam Pharmaceuticals Inc.1$135
Grifols USA, LLC1$129
Natus Medical Incorporated2$44
Genentech USA, Inc.1$43
EMD Serono Research & Development Institute, Inc.1$32

How this compares

$7,863,892 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$231,996
Medicare patients
105
Services billed
30,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Tampa

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →